Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts

Experimental Lung Research

Volumn 36, Issue 2, 2010, Pages 120-128

  Lin, Qing ^a   Fang, Li Ping ^a   Zhou, Wei Wei ^a   Liu, Xin Min ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Human lung fibroblasts; Migration; Peroxisome proliferator activated receptor gamma; Phenotypic differentiation; Proliferation; Rosiglitazone

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR BB; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; LUNG FIBROSIS; MYOFIBROBLAST; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM;

CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; LUNG; PHENOTYPE; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PPAR GAMMA; PULMONARY FIBROSIS; SERUM; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77749249238     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902140903214659     Document Type: Article

References (20)

1. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ: Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395-417.
2. Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8.
3. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
4. Rizzo G, Fiorucci S: PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol. 2006;6:421-427.
5. Belvisi MG, Hele DJ, Birrell MA: Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol. 2006;533:101-109.
6. Becker J, Delayre-Orthez C, Frossard N, Pons F: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol. 2006;20:429-447.
7. Agostini C, Gurrieri C: Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3:357-363.
8. Scotton CJ, Chambers RC: Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132:1311-1321.
9. Liu D, Zeng BX, Zhang SH, Yao SL: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res. 2005;54:464-470.
10. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H: The peroxisome proliferator-activated receptor gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid defined diet. Hepatol Res. 2005;32:235-242.
11. Henderson BC, Sen U, Reynolds C, Moshal KS, Ovechkin A, Tyagi N, Kartha GK, Rodriguez WE, Tyagi SC: Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. Int J Biol Sci. 2007;3:385-392.
12. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC: PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant. 2006;21:2399-2405.
13. Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P, Sortino M, Crimi N, Caputi AP, Thiemermann C, Vancheri C: Effect of rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J. 2005;25:225-234.
14. Angeli V, Hammad H, Staels B, Capron M, Lambrecht BN, Trottein F: Peroxisome proliferators-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. J Immunol. 2003;170:5295-5301.
15. Ward JE, Gould H, Harris T, Bonacci JV, Stewart AG: PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol. 2004;141:517-525.
16. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 2004;23:100-108.
17. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy RC: PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L891-L901.
18. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL: PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol. 2006;290:H390-H397.
19. Solini A, Santini E, Madec S, Nannipieri M, Bonotti A, Cuccato S, Ferrannini E: Rosiglitazone increases matrix production and quenches inflammation: studies in human cells. Diabetes Metab Res Rev. 2008;24:197-204.
20. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M, Galli A, Serio M, Luconi M: A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha (TNF-α) and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:718-724.